Article thumbnail

Data from: A survey of risk tolerance to multiple sclerosis therapies

By Robert J. Fox, Carol Cosenza, Lauren Cripps, Paul Ford, MaryBeth Mercer, Sneha Natarajan, Amber Salter, Tuula Tyry and Stacey S. Cofield

Abstract

Objective: To determine tolerance to various risk scenarios associated with current MS therapies. Methods: People with MS from the North American Research Committee on Multiple Sclerosis (NARCOMS) Registry’s online cohort and the National Multiple Sclerosis Society were invited to complete a questionnaire on tolerance to real-world risks associated with a hypothetical therapy. Multiple risks levels were presented including, skin rash, infection, kidney injury, thyroid injury, liver injury, and PML. Results: Both progressive multifocal leukoencephalopathy (PML) and kidney injury had lowest risk tolerance at 1:1,000,000 and thyroid and infection risks had highest tolerance at 1:1,000. Males, younger age and participants with greater disability reported a higher tolerance to all risk scenarios. Those that were currently taking a MS therapy reported higher tolerance than those not taking any therapy. Participants taking infusion therapies reported high tolerance to all risks and those taking injectables reported a lower tolerance. Conclusion: People with MS displayed a wide range of RT for MS therapies. Our study identified sex, age, disability and current DMT use to be associated with RT

Topics: Life sciences, medicine and health care, Life sciences, medicine and health care
Publisher: Data Archiving and Networked Services (DANS)
DOI identifier: 10.5061/dryad.tg142pt
OAI identifier:
Provided by: NARCIS
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://easy.dans.knaw.nl/oai (external link)
  • http://datacite.org/schema/ker... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.